SCHEMBL1241741

SCHEMBL1241741

COc1ccc(-c2cc(OC(F)(F)F)ccc2-c2cccc(N(Cc3ccc(C(C)(C)C)cc3)C(=O)C(=O)O)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 8/20 0.51
LTB4R2 Q9NPC1 1/20 0.45
NR1H4 Q96RI1 5/20 0.42
GCGR P47871 2/20 0.40
GIPR P48546 2/20 0.40
GLP1R P43220 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
PTGES O14684 1/20 0.39
ALOX5 P09917 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1241376 0.86 SERPINE1 (0.65) SERPINE1LTB4R2NR1H4GCGRGIPR
SCHEMBL1241763 0.81 SERPINE1 (0.60) SERPINE1NR1H4GCGRGIPRGLP1R
SCHEMBL1242460 0.81 SERPINE1 (0.65) SERPINE1NR1H4GCGRGIPRGLP1R
SCHEMBL1242259 0.81 SERPINE1 (0.60) SERPINE1NR1H4GCGRGIPRGLP1R
SCHEMBL1241739 0.80 SERPINE1 (0.51) SERPINE1LTB4R2NR1H4GCGRGIPR
SCHEMBL1242274 0.79 NR1H4 (0.52) SERPINE1LTB4R2NR1H4GCGRGIPR
SCHEMBL1241748 0.79 SERPINE1 (0.60) SERPINE1NR1H4GCGRGIPRGLP1R
SCHEMBL1242687 0.79 SERPINE1 (0.56) SERPINE1NR1H4GCGRGIPRGLP1R
SCHEMBL1241585 0.79 SERPINE1 (0.59) SERPINE1NR1H4GCGRGIPRGLP1R
SCHEMBL1241449 0.79 SERPINE1 (0.77) SERPINE1NR1H4GCGRGIPRGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885LTB4R2 1577/4885NR1H4 4184/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885LTB4R2 1577/4885NR1H4 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.